Proton pump inhibitors for gastroesophageal reflux disease
Pro Research Analysisby 
Searched over 200M research papers
Proton Pump Inhibitors (PPIs) for Gastroesophageal Reflux Disease (GERD) Treatment
Proton pump inhibitors (PPIs) are widely recognized as the primary pharmaceutical treatment for gastroesophageal reflux disease (GERD), effectively reducing symptoms such as heartburn, regurgitation, and esophagitis, and improving patients’ quality of life Sharma2024Howland2023. PPIs work by suppressing gastric acid production, which helps prevent acid from damaging the esophagus.
Efficacy of PPIs in GERD: Esophageal Healing and Symptom Relief
PPIs are particularly effective in patients with erosive esophagitis, who tend to show excellent response rates. Patients with non-erosive reflux disease (NERD) and abnormal reflux parameters also benefit from PPI therapy, though those without objective evidence of abnormal reflux may experience less symptom relief . Meta-analyses show that higher daily doses of PPIs improve esophageal healing and symptom resolution in both the short and long term, although the benefit of twice-daily dosing compared to once-daily dosing remains unclear and requires further study .
Diagnostic Use of Short-Term PPI Therapy
A short-term trial of PPI therapy is sometimes used to help diagnose GERD. However, the accuracy of this approach is limited. While a positive response to PPIs has moderate sensitivity, its specificity is low, meaning that a good response does not definitively confirm GERD when compared to objective diagnostic standards like 24-hour pH monitoring .
Long-Term PPI Use: Risks and Recommendations
Chronic use of PPIs has been associated with potential adverse effects, though most reported risks are based on associations rather than proven causation Gyawali2017Howland2023. Current clinical guidelines recommend establishing clear indications before starting long-term PPI therapy and suggest regular reassessment to ensure ongoing need Gyawali2017Howland2023. The risks and benefits should be carefully weighed, especially in patients without clear evidence of acid-related disease.
PPI-Refractory GERD: Alternative and Adjunctive Therapies
A significant proportion of GERD patients—up to 40%—may not respond fully to PPI therapy Mermelstein2018Hillman2017. Causes of PPI-refractory GERD include poor adherence, persistent acid or nonacid reflux, functional disorders, and variations in PPI metabolism Mermelstein2018Hillman2017. For these patients, additional evaluation and alternative treatments may be necessary. Options include:
- Adjunctive Medications: Adding prokinetic agents like domperidone to PPI therapy can further reduce GERD symptoms without increasing adverse events . Other adjunctive therapies, such as histamine-2 receptor antagonists, promotility agents, and mucosal protective agents, have shown mixed results .
- Personalized Therapy: Considering PPI metabolizer genotype or switching to PPIs less affected by genetic variation (e.g., rabeprazole, esomeprazole) may improve outcomes in some patients .
- Procedural Interventions: For persistent symptoms, procedures like laparoscopic fundoplication or endoscopic treatments may be considered .
Newer Therapies and Comparative Effectiveness
While PPIs remain the first-line therapy for GERD, newer agents such as vonoprazan, a potassium-competitive acid blocker, have been introduced in some regions and are being compared to PPIs for efficacy in healing GERD . However, PPIs continue to be the standard recommendation in most guidelines .
Conclusion
PPIs are highly effective for most patients with GERD, especially those with erosive disease or abnormal reflux. Higher daily doses can improve outcomes, but the benefit of twice-daily dosing is not yet clear. Long-term PPI use should be carefully considered due to potential risks, and alternative or adjunctive therapies may be needed for patients who do not respond to standard PPI treatment. Ongoing research and individualized patient assessment remain key to optimizing GERD management Gyawali2017Nguyen2024Sharma2024+4 MORE.
Sources and full results
Most relevant research papers on this topic
DOI
DOI